Jonsson Comprehensive Cancer Center

442 total trials 357 currently recruiting 39 completed

Trial Pipeline

RECRUITING NA

Virtual Reality vs. Music Relaxation for Reducing Anxiety and Pain During Breast Biopsies

NCT07310004

RECRUITING Phase 3

Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment

NCT07293585

RECRUITING Phase 2

Alpha-Emitting Radionuclide or Beta-Emitting Radionuclide With Metastasis-Directed Stereotactic Body Radiotherapy for the Treatment of Recurrent, Oligometastatic Prostate Adenocarcinoma

NCT07150715

RECRUITING Early Phase 1

Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma

NCT07235280

RECRUITING NA

Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial

NCT07276438

RECRUITING Early Phase 1

Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial

NCT07164027

RECRUITING Phase 3

Advanced Imaging Techniques for Evaluating the Tumor Immune Microenvironment in Glioblastoma Patients

NCT07461948

RECRUITING Phase 4

A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients

NCT06934239

RECRUITING Phase 2

An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.

NCT07185165

RECRUITING NA

Advanced Magnetic Resonance Imaging for the Identification of Recurrent Brain Tumors and Radiation Necrosis

NCT07339085

RECRUITING Phase 1

Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers

NCT07118176

RECRUITING Phase 1

External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer

NCT06543576

RECRUITING Phase 1

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

NCT07089641

RECRUITING

Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity

NCT07077239

RECRUITING Phase 2

Ivonescimab for the Treatment of Thymic Cancer

NCT06980077

RECRUITING NA

Computed Tomography-Guided Stereotactic Body Radiation Therapy With Intrafraction Motion Monitoring for the Treatment of Localized Prostate Cancer, ILLUSION Trial

NCT06995053

RECRUITING Phase 1

Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

NCT06810778

RECRUITING NA

A Clinic-wide Intervention (Primary Care-GI Connect) for Improving Rates of Colonoscopy After Abnormal Fecal Immunochemical Test Result in Patients at Federally Qualified Health Centers

NCT06568016

RECRUITING Phase 2

Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms

NCT06788938

RECRUITING Phase 1

Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer

NCT06225011

RECRUITING Phase 1

Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial

NCT06432036

RECRUITING Phase 1

Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors

NCT06650163

RECRUITING NA

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal)

NCT06572423

RECRUITING Phase 2

An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer

NCT06447103

RECRUITING Phase 2

Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT)

NCT06216249

RECRUITING Phase 2

Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial

NCT06288113

RECRUITING NA

Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers

NCT06538337

RECRUITING Phase 2

Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors

NCT06113016

RECRUITING Phase 2

Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer

NCT05775471

RECRUITING Phase 2

Study of Magnetic Resonance Image and Computed Tomography-Guided Stereotactic Body Radiation Therapy for Abdominopelvic Sarcomas (MARS Trial)

NCT06436612

RECRUITING Phase 1

Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy

NCT05398302

RECRUITING Phase 2

Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial

NCT06067269

RECRUITING

An Organoid-based Functional Precision Medicine Trial in Osteosarcoma

NCT06064682

RECRUITING NA

Improving Colonoscopy Surveillance for Patients With High Risk Colon Polyps

NCT06376565

RECRUITING Phase 1

Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells

NCT06059690

RECRUITING NA

Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible Participants

NCT05978128

RECRUITING Phase 2

Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors

NCT05595499

RECRUITING Phase 1

Zimberelimab and Quemliclustat in Combination With Chemotherapy for the Treatment of Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma

NCT05688215

RECRUITING Phase 1

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

NCT05256641

RECRUITING Phase 1

An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer

NCT05558904

RECRUITING NA

Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma

NCT06090903

RECRUITING Phase 1

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

NCT05319873

RECRUITING NA

High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma

NCT04945642

RECRUITING Phase 2

Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia

NCT04712851

RECRUITING Phase 2

Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy

NCT04915508

RECRUITING Early Phase 1

99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer

NCT04857502

RECRUITING

Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification

NCT04765150

RECRUITING Phase 1

Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer

NCT04703101

RECRUITING Phase 2

Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer

NCT04469764

RECRUITING Phase 2

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer

NCT04553770

RECRUITING Phase 1

Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer

NCT04473781

RECRUITING NA

A Study to See if an iPhone Weight Management App Can Help Promote Weight Loss in Adolescents and Young Adults After a Stem Cell Transplant

NCT04453072

RECRUITING

Brain Health in Breast Cancer Survivors

NCT04297020

RECRUITING

Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer

NCT04742608

RECRUITING Phase 2

Pembrolizumab in Treating Participants With Leukoplakia

NCT03603223

RECRUITING NA

Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort

NCT02701153

RECRUITING

Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer

NCT02280161

RECRUITING

Active Surveillance for Cancer of the Prostate (ASCaP)

NCT00949819

ACTIVE NOT RECRUITING Phase 1

A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma

NCT06342908

ACTIVE NOT RECRUITING

Registry of Patients Undergoing Cryoablation for Early Stage Breast Cancer

NCT06387173

ACTIVE NOT RECRUITING NA

Psychoeducation for Uveal Melanoma

NCT06075589

ACTIVE NOT RECRUITING NA

Malnutrition Screening and Dietary Intervention to Improve Nutrition Outcomes in Patients With Unresectable Pancreatic Cancer

NCT06090916

ACTIVE NOT RECRUITING Phase 2

177-Lutetium-PSMA Before Stereotactic Body Radiotherapy for the Treatment of Oligorecurrent Prostate Cancer, The LUNAR Study

NCT05496959

ACTIVE NOT RECRUITING NA

Pea Protein Oral Nutrition Supplement for the Reduction of Gastrostomy Tube Placement Rate in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiation Therapy

NCT05115760

ACTIVE NOT RECRUITING Early Phase 1

Image-Guided (68Ga-PSMA-11 PET/CT) Prostate Biopsy for the Diagnosis of Prostate Cancer in Men With Prior Negative/Inconclusive Biopsy

NCT05160597

ACTIVE NOT RECRUITING Early Phase 1

Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma

NCT05045027

ACTIVE NOT RECRUITING Phase 2

Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer

NCT03902951

ACTIVE NOT RECRUITING Phase 1

Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

NCT04285671

ACTIVE NOT RECRUITING NA

Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity Following Prostate Radiotherapy, GARUDA Trial

NCT04624256

ACTIVE NOT RECRUITING NA

Micro-Ultrasound for the Detection and Localization of Prostate Cancer Tumors in Patients Undergoing Radical Prostatectomy

NCT04299620

ACTIVE NOT RECRUITING Phase 1

Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma

NCT04420975

ACTIVE NOT RECRUITING Phase 1

Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation

NCT04457232

ACTIVE NOT RECRUITING Early Phase 1

68Ga-FAPi-46 PET/CT Scan in Imaging Patients With Sarcoma

NCT04457258

ACTIVE NOT RECRUITING Phase 1

Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers

NCT04459273

ACTIVE NOT RECRUITING Phase 2

Brachytherapy With Durvalumab or Tremelimumab for the Treatment of Patients With Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies

NCT04395079

ACTIVE NOT RECRUITING Phase 1

Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma

NCT04299113

ACTIVE NOT RECRUITING

CT-guided Stereotactic Body Radiation Therapy and MRI-guided Stereotactic Body Radiation Therapy for Prostate Cancer, MIRAGE Study

NCT04384770

ACTIVE NOT RECRUITING Early Phase 1

Focal Laser Ablation of Prostate Cancer

NCT04305925

ACTIVE NOT RECRUITING Phase 1

Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma

NCT04201873

ACTIVE NOT RECRUITING Early Phase 1

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues

NCT04147494

ACTIVE NOT RECRUITING NA

Implementation Research to Increase Colorectal Cancer Screening Rates Among Low Income and Ethnic Minority Groups

NCT06090643

ACTIVE NOT RECRUITING Phase 1

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

NCT04007029

ACTIVE NOT RECRUITING Phase 1

CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients With Stage IV Non-small Cell Lung Cancer

NCT03546361

ACTIVE NOT RECRUITING Phase 2

CPX-351 Plus Enasidenib for Relapsed AML

NCT03825796

ACTIVE NOT RECRUITING Phase 2

Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer

NCT03732950

ACTIVE NOT RECRUITING Phase 1

Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

NCT03830918

ACTIVE NOT RECRUITING Phase 2

Stereotactic Body Radiation Therapy in Treating Patients With Localized Prostate Cancer That Have Undergone Surgery

NCT03541850

ACTIVE NOT RECRUITING Phase 1

Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate

NCT03582475

ACTIVE NOT RECRUITING

SPECT/CT for the Characterization of Renal Masses

NCT03996850

ACTIVE NOT RECRUITING Phase 2

Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

NCT03672773

ACTIVE NOT RECRUITING Phase 2

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

NCT03601455

ACTIVE NOT RECRUITING Phase 3

Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical Prostatectomy

NCT03582774

ACTIVE NOT RECRUITING Phase 2

Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer

NCT02881242

ACTIVE NOT RECRUITING Phase 1

Astra Zeneca (Immuno Stereotactic Ablative Body Radiotherapy) ISABR Study: Randomized Phase I/II Study of Stereotactic Body Radiotherapy

NCT03148327

ACTIVE NOT RECRUITING Phase 2

Soylent in Reducing Gastrostomy Tube Rates in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiotherapy

NCT07242365

ACTIVE NOT RECRUITING

Randomized Trial Comparing Performance of Molecular Markers for Indeterminate Thyroid Nodules

NCT02681328

ACTIVE NOT RECRUITING NA

Low-Fat Diet and Fish Oil in Men on Active Surveillance for Prostate Cancer

NCT02176902

ACTIVE NOT RECRUITING Phase 2

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

NCT01990196

ACTIVE NOT RECRUITING NA

Stereotactic Body Radiation Therapy in Treating Patients With Localized High-Risk Prostate Cancer

NCT02296229

ACTIVE NOT RECRUITING NA

Anal Cytology Collection Procedures in Predicting High-Grade Anal Dysplasia in Men Who Have Sex With Men

NCT02816879

What the Pipeline for Jonsson Comprehensive Cancer Center Shows

According to the ClinicalTrials.gov registry, Jonsson Comprehensive Cancer Center is linked to 442 US clinical trials across every stage of research activity. Of those, 357 studies are currently recruiting — about 81% of the sponsor's indexed portfolio — and 39 are already marked complete, representing roughly 9% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.

The phase mix for Jonsson Comprehensive Cancer Center reports 7 late-stage studies (Phase 3 and Phase 4 combined) and 335 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.

The top therapeutic focus area indexed for Jonsson Comprehensive Cancer Center is Prostate Carcinoma with 10 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial